您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > 5-Iodotubercidin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
5-Iodotubercidin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
5-Iodotubercidin图片
包装与价格:
包装价格(元)
5mg电议
50mg电议

产品介绍
5-Iodotubercidin (NSC 113939) 是一种 ATP 模拟物,是一种有效的腺苷激酶抑制剂,IC50 为 26 nM。 5-Iodotubercidin (NSC 113939) 通过引起磷酸化酶的失活和糖原合酶的活化来启动分离的肝细胞中的糖原合成。 5-Iodotubercidin (NSC 113939) 还抑制 CK1、胰岛素受体酪氨酸激酶、磷酸化酶激酶、PKA、CK2、PKC 和 Haspin。

Cell lines

MEFs and HCT116 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

0 ~ 2.5 μM; 8 hrs

Applications

In both MEFs and HCT116 cells, 5-Iodotubercidin up-regulated p53 expression. Moreover, dosage experiments indicated that 5-Iodotubercidin was able to up-regulate p53 expression at the concentration as low as 0.25 μM. In HCT116 cells with ADK knocked out, the decrease of ADK levels did not significantly change the protein levels of p53, which indicated that 5-Iodotubercidin-induced p53 upregulation was not contributed to direct inhibition of ADK.

Animal models

Nude mice bearing HCT116 cells

Dosage form

0.625 or 2.5 mg/kg; i.p.

Applications

In nude mice bearing HCT116 cells, 5-Iodotubercidin at 2.5 mg/kg induced rapid tumor regression. However, 5-Iodotubercidin treatment also decreased the body weight of mice (a reduction of 6% at the end of treatment). Moreover, 5-Iodotubercidin showed inhibition on p53-/- HCT116-initiated tumors as well. At a lower dose of 0.625 mg/kg, 5-Iodotubercidin still showed an inhibition effect on tumor growth but p53-/- HCT116 exhibited resistance to 5-Iodotubercidin.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

5-Iodotubercidin (Itu) is a purine derivative and hence an inhibitor of adenosine kinase with an IC50 value of 26 nM [1].

Adenosine kinase is important in regulating the intracellular and extracellular concentrations of adenosine and hence diverse physiological actions of adenosine [2].

In various cells such as cancer cells, persisted AMPK activation could result in apoptosis [4]. In nude mice with colon carcinoma xenograft, Itu at a dose of 2.5 mg/kg resulted in rapid tumor regression compared with the control group. At the dose of 0.625 mg/kg, Itu still inhibited tumor growth, but p53-/- tumors were resistant to Itu at this lowered dose [1].

In male Wistar rat hepatocytes, incubation with Itu resulted in concentrations of AMP and ATP at 0.39 ± 0.06 and 1.51 ± 0.10 μmol/g cell wet mass, respectively; while control incubation at 0.27 ± 0.05 and 2.25 ± 0.33 μmol/g cell wet mass, respectively. Addition of 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) and Itu simultaneously resulted in almost the same effect of Itu alone. It was probable that Itu inhibited adenosine kinase and blocked the synthesis of 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP) from AICAR. ZAM is a structural AMP analogue and hence mimics the effect of AMP on the AMP-activated protein kinase (AMPK) activation [3].

References:
[1].  Xin Zhang, Deyong Jia, Huijuan Liu, et al. Identification of 5-Iodotubercidin as a Genotoxic Drug with Anti-Cancer Potential. PLOS ONE, 2013, 8(5):e62527.
[2].  Jaoek Park and Radhey S. Gupta. Adenosine: A Key Link between Metabolism and Brain Activity: Adenosine Metabolism, Adenosine Kinase, and Evolution. New York: Springer Science+Business Media, 2013.
[3].  García-Villafranca J. and Castro J. Effects of 5-iodotubercidin on hepatic fatty acid metabolism mediated by the inhibition of acetyl-CoA carboxylase. Biochem. Pharmacol., 2002, 63(11):1997-2000.
[4].  Haiyan Chen, Ji-ping Wang, Richard J. Santen, et al. Adenosine monophosphate activated protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-term estrogen deprived breast cancer cells. Apoptosis, 2015, 20:821-830.